<DOC>
	<DOCNO>NCT00125164</DOCNO>
	<brief_summary>This study intend determine whether twice daily weight base dose recombinant human insulin-like growth factor ( rhIGF-1 ) safely effectively increase growth prepubertal child short stature associate low IGF-1 level produce sufficient growth hormone ( GH ) . Subjects randomize either observation arm active treatment .</brief_summary>
	<brief_title>Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 ( IGF-1 ) Deficiency</brief_title>
	<detailed_description>Prepubertal growth failure associate primary IGF-1 deficiency ( IGFD ) . Primary IGFD term use describe patient intrinsic cellular defect GH action . In protocol , primary IGFD define short stature ( height standard deviation score [ SDS ] &lt; -2 mean age gender ) , low serum IGF-1 ( IGF-1 SDS &lt; -2 mean age gender ) , level growth hormone ( GH ) normal ( ≥7ng/mL ) GH stimulation test . Primary IGFD believe result low normal ability produce IGF-1 expose normal level GH , i.e. , type GH insensitivity GH resistance . This trial one year , randomize , open label , observation-controlled , parallel-dose comparison efficacy safety study conduct approximately 40 center across United States .</detailed_description>
	<mesh_term>Growth Disorders</mesh_term>
	<mesh_term>Failure Thrive</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Chronological age ≥ 3 chronological bone age less equal 11 year inclusive girl ; Chronological age ≥ 3 chronological bone age less equal 12 year inclusive boy Prepubertal Height SD score &lt; 2 IGF1 SD score &lt; 2 Prior treatment rhGH , rhIGF1 , growthinfluencing medication Growth failure associate identifiable cause ( e.g. , syndrome , chromosomal abnormality ) Chronic illness diabetes , cystic fibrosis , etc .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Primary IGF-1 Deficiency</keyword>
</DOC>